{"product_id":"biocon-swot-analysis","title":"Biocon SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBiocon's robust R\u0026amp;D pipeline and strong manufacturing scale position it well in biologics and biosimilars, but pricing pressure, regulatory complexities, and rising competition create execution risks; strategic partnerships and expansion into novel therapeutics could unlock growth. Discover the full SWOT analysis for a research-backed, editable report and Excel matrix to inform investment, strategy, and due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Biosimilars Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiocon, after fully integrating Viatris’ biosimilars unit in 2023, holds a dominant global biosimilars portfolio with end-to-end R\u0026amp;D-to-commercial capabilities across key molecules like trastuzumab and bevacizumab.\u003c\/p\u003e\n\u003cp\u003eSynergies lifted biosimilars revenue by ~28% in FY2025 to INR 5,900 crore (≈USD 730m), driving higher US and EU market share and supporting double-digit operating margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust CDMO Services via Syngene\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSyngene International, Biocon's CDMO (contract development and manufacturing organization), generated about $321 million revenue in FY2024-25, supplying diversified, repeatable income via CRO and CMO services.\u003c\/p\u003e\n\u003cp\u003eWith global pharma outsourcing rising—outsourced R\u0026amp;D market ~USD 50 billion in 2024—Syngene’s 200,000+ sq ft state-of-the-art facilities and integrated discovery-to-commercialization chain give Biocon a strong cost-competitive edge.\u003c\/p\u003e\n\u003cp\u003eHigher-margin CDMO work lifted Biocon Group’s operating mix, making Syngene a core pillar of financial stability and growth, contributing roughly 25–30% of consolidated EBITDA in 2024–25.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Efficient Manufacturing Excellence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiocon runs some of the largest bio-manufacturing sites in India and Malaysia, producing over 1.2 billion units annually and enabling per-unit cost advantages that undercut many smaller rivals by 15–25% as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese plants scale biosimilar output—insulin, monoclonal antibodies—and drove Biocon Biologics to report a 2024 revenue of INR 3,450 crore in manufacturing, supporting EBITDA margins near 28%.\u003c\/p\u003e\n\u003cp\u003eStrategic locations cut operating costs via lower labor and utility expenses while meeting US FDA and EU GMP standards, sustaining cost leadership in global biosimilar markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeadership in Diabetes Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpbiocon leads global insulin care with glargine aspart and lispro supplying affordable biologics that cut payer costs win large public tenders revenue from products reached in fy2024 rising year-on-year.\u003e\n\u003cpby late biocon secured multiple fda interchangeability designations in the us lifting its insulin market share to about and accelerating hospital formulary adoption.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003ePortfolio: Glargine, Aspart, Lispro\u003c\/li\u003e\n\u003cli\u003eFY2024 insulin revenue: $420M (+18% YoY)\u003c\/li\u003e\n\u003cli\u003eUS market share (late 2025): ~7%\u003c\/li\u003e\n\u003cli\u003eInterchangeability: multiple FDA approvals\u003c\/li\u003e\n\n\u003c\/pby\u003e\u003c\/pbiocon\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Research and Development Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiocon invests ~₹2.1 billion annually in R\u0026amp;D (2024), targeting complex biologics and next-gen novel molecules, keeping late-stage immunology and oncology assets aimed at 2026–2027 commercialization.\u003c\/p\u003e\n\u003cp\u003eThis pipeline supports revenue renewal as base biosimilars face price erosion; several assets could add low-single-digit to mid-single-digit percentage points to group revenue by 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e₹2.1B R\u0026amp;D (2024)\u003c\/li\u003e\n\u003cli\u003eLate-stage immunology\/oncology—2026–2027\u003c\/li\u003e\n\u003cli\u003eOffsets biosimilar price declines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiocon scales margins: FY25 biosimilars ₹5,900cr, Syngene $321M, 1.2B units\/yr\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiocon’s integrated biosimilars+CDMO model drives scale and margins: FY2025 biosimilars revenue INR 5,900 crore (+28%), Syngene revenue $321M (FY2024-25), group manufacturing output 1.2B units\/year, insulin revenue $420M (FY2024, +18%), R\u0026amp;D ₹2.1B (2024) with late-stage assets due 2026–27.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 biosimilars rev\u003c\/td\u003e\n\u003ctd\u003eINR 5,900 cr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSyngene rev\u003c\/td\u003e\n\u003ctd\u003e$321M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing output\u003c\/td\u003e\n\u003ctd\u003e1.2B units\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsulin rev FY2024\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e₹2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Biocon’s internal strengths and weaknesses alongside external opportunities and threats, mapping its competitive position, growth drivers, operational gaps, and market risks to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Biocon SWOT snapshot for rapid strategic alignment, ideal for executives and teams needing a clear, editable overview to support quick decisions and stakeholder-ready presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe massive 2023 acquisition of Viatris’ biosimilars unit pushed Biocon’s long-term debt to about ₹58,000 crore and net interest cost above ₹3,200 crore in FY2024-25, raising the debt-to-equity ratio to roughly 2.1 by Q3 2025; deleveraging via a ₹3,000 crore equity raise and selective asset sales is underway, but leverage still worries investors, and high fixed obligations limit capacity for further large-scale acquisitions in the near term.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiocon has faced multiple US FDA inspection observations and two FDA warning letters since 2013, most recently resulting in plant remediation that delayed a 2023 biosimilar approval by ~9 months and cost ~USD 25–30m in remediation and lost sales.\u003c\/p\u003e\n\u003cp\u003eRecurring compliance gaps risk further delays into high-margin US\/EU markets, potentially cutting FY2025 biosimilars revenue growth by several percentage points and disrupting supply chains for insulin and mAb lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNarrow Product Concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa significant share of biocon revenue still comes from a few biosimilars and pegfilgrastim together accounted for about fy2024 consolidated sales crore concentrating earnings risk.\u003e\n\u003cpany market-share loss or a pricing squeeze in these molecules would cut group revenue by so quarterly results swing sharply on competitive moves and tender pricing.\u003e\n\u003cpdiversification into oncology immunology and novel biologics is ongoing but new therapeutic contributions remained under of sales in leaving the revenue base still concentrated.\u003e\n\u003c\/pdiversification\u003e\u003c\/pany\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMargin Compression in Generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBiocon faces margin compression in generics as global price competition and biosimilar entry push down ASPs; industry-wide generic prices fell ~12% y\/y in key markets in 2024, squeezing margins despite scale.\u003c\/p\u003e\n\u003cp\u003eGovernment price controls (India’s NPPA and tender caps in EU) plus aggressive bids from Amgen, Sandoz and Indian rivals press margins; Biocon’s FY2024 API\/generics segment EBIT margin narrowed toward mid-teens.\u003c\/p\u003e\n\u003cp\u003eSustaining high double-digit margins needs ongoing R\u0026amp;D, process wins, and cost cuts—hard to keep forever given 5–8% annual price erosion in many tender markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeneric ASPs down ~12% y\/y (2024)\u003c\/li\u003e\n\u003cli\u003eFY2024 generics\/API EBIT margin: mid-teens\u003c\/li\u003e\n\u003cli\u003eTender market price erosion: 5–8% annually\u003c\/li\u003e\n\u003cli\u003eCompetition: Amgen, Sandoz, Indian contract manufacturers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Integration Complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpmanaging a diverse global workforce and integrating viatris commercial units has strained biocon operations with integration costs of about booked in fy2024-25 headcount rising to employees as dec\u003e\n\u003cpdiscrepant management styles and country-specific regs slowed three planned global launches in delaying expected revenue of\u003e\n\u003cpbiocon must refine structures between its bengaluru hq and international offices to cut launch inefficiencies aim reduce time-to-market by\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegration costs ~$120m (FY2024-25)\u003c\/li\u003e\n\u003cli\u003eHeadcount +18% to 12,400 (Dec 2025)\u003c\/li\u003e\n\u003cli\u003eThree launches delayed, ~$40m revenue impact (2025)\u003c\/li\u003e\n\u003cli\u003eTarget: reduce time-to-market 25%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pbiocon\u003e\u003c\/pdiscrepant\u003e\u003c\/pmanaging\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh debt and product concentration strain cash flow as generics drag margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh leverage after the 2023 Viatris buy (~₹58,000 crore debt; net interest \u0026gt;₹3,200 crore FY2024-25) and ongoing remediation costs from FDA issues have tightened cash flow, while revenue concentration (Trastuzumab + Pegfilgrastim ~28% of FY2024 sales) and 2024 generic ASP declines (~12% y\/y) raise margin and growth risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e≈₹58,000 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet interest FY24-25\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;₹3,200 crore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentration\u003c\/td\u003e\n\u003ctd\u003eTrastuzumab+Pegfilgrastim 28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric ASP change 2024\u003c\/td\u003e\n\u003ctd\u003e−12% y\/y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eBiocon SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it reflects the real, structured content included in your download. Buy now to unlock the complete, editable version with in-depth insights on Biocon's strengths, weaknesses, opportunities, and threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752754655609,"sku":"biocon-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biocon-swot-analysis.png?v=1772244949","url":"https:\/\/matrixbcg.com\/products\/biocon-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}